Latest Heart Failure News

Page 2 of 8
Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.
Ada Torres
Ada Torres
27 July 2026
EBR Systems has launched the WiSE Coupler in the US, a new accessory designed to improve the implantation of its wireless cardiac pacing electrode. The device has FDA clearance and was piloted in 10 procedures, marking another step in the company’s US commercial expansion.
Ada Torres
Ada Torres
24 July 2026
Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.
Ada Torres
Ada Torres
10 July 2026
Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.
Ada Torres
Ada Torres
1 July 2026
Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.
Ada Torres
Ada Torres
1 July 2026
Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.
Ada Torres
Ada Torres
25 June 2026
Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.
Ada Torres
Ada Torres
25 June 2026
Echo IQ has locked in a binding Heads of Agreement with Pro Medicus for a strategic A$20 million investment and a US commercial partnership to accelerate adoption of its AI-powered cardiac diagnostic platform.
Ada Torres
Ada Torres
25 June 2026
EBR Systems has wrapped up the retail tranche of its fully underwritten entitlement offer, adding A$10.9 million to a total raise of about A$43.6 million to support its wireless cardiac pacing technology.
Ada Torres
Ada Torres
24 June 2026
Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.
Ada Torres
Ada Torres
12 June 2026
ImpediMed has successfully closed an oversubscribed Share Purchase Plan, raising $2.1 million following a $13.2 million institutional placement. The strong shareholder response underscores confidence ahead of a key shareholder vote.
Ada Torres
Ada Torres
10 June 2026
EBR Systems has secured A$106.4 million through a fully underwritten institutional placement and entitlement offer, positioning the company for further commercial expansion of its wireless cardiac pacing technology.
Ada Torres
Ada Torres
5 June 2026

Browse the archive

Full archive